Dreamtech Recovers Performance Fundamentals... Semiconductor and Medical Device Growth Momentum Accelerates
Operating Profit Surpasses Last Year by Q3
Corporate Value May Be Reassessed with New Business Expansion
Dreamtech, a manufacturer of IT components based on smartphone modules and medical devices, is expected to re-enter a growth trajectory as new business revenues begin to materialize in 2026, following a rebound in performance this year. Analysts suggest that the simultaneous diversification of revenue streams in both the memory module and medical device segments has increased the potential for a revaluation of the company's corporate value.
On December 8, Kiwoom Securities projected that Dreamtech's sales and operating profit for this year would reach 1.2558 trillion won and 39.2 billion won, respectively, representing year-on-year growth of 7% and 67%. While last year's performance was somewhat sluggish due to a slowdown in global IT demand, the company is expected to see a rebound in both scale and profitability this year.
The third quarter results signaled a turnaround. Sales reached 322.5 billion won, down 2% year-on-year, but operating profit rose 38% to 10.6 billion won. Cumulative operating profit for the first three quarters reached 29.3 billion won, already surpassing last year's annual figure of 23.6 billion won.
There were concerns that the inventory strategies of client companies in response to North American tariff risks would have only a short-term effect, but demand in the third quarter remained at last year's level, demonstrating that "real demand is still alive." The CCM division also continued to deliver stable results thanks to improved manufacturing efficiency at affiliate Namuga.
In the fourth quarter, the full-scale mass production of memory modules at the India plant is expected to further enhance cost savings, and a reduction in losses at subsidiary Cardiac Insight is also anticipated.
Oh Hyunjin, a researcher at Kiwoom Securities, stated, "This year's turnaround is not a temporary rebound but appears to be a structural improvement in fundamentals," adding, "In particular, growth in the BHC (bio-healthcare equipment module) segment will be key to determining mid- to long-term performance."
From 2026, Dreamtech's existing IT and mobile-centric business structure is expected to diversify through the expansion of new businesses such as medical devices and semiconductor modules.
Shinhan Investment Corp. estimates Dreamtech's 2026 sales at 1.488 trillion won and operating profit at 59.8 billion won, representing growth of 18% and 52% year-on-year, respectively. In particular, with the full-scale growth of memory modules and medical devices, the operating margin is expected to improve by 0.7 percentage points year-on-year to 3.8%.
After completing its India plant, Dreamtech quickly secured client approvals and is expanding production from server RDiMMs to desktop UDiMMs and laptop SODiMMs. At full capacity, the annual production capability is estimated at 200 billion won. This new business is expected to boost the IMC (IT and mobile) segment's scale and, by entering the semiconductor category, serve as a factor for corporate value revaluation.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Oh Gangho, a researcher at Shinhan Investment Corp., stated, "After confirming the recovery in 2025, Dreamtech is expected to enter a new valuation range in 2026 as new business revenues are fully realized," adding, "In particular, further expansion in semiconductors and medical devices will be the key momentum for the stock price."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.